摘要
This prospective multicenter phase II study evaluated the clinical efficacy of neoadjuvant nivolumab-exclusive (N) and nivolumab-chemotherapy (N/C) combinations based on PD-L1 expression. Eligible patients exhibited resectable clinical stage IIA-IIIB (AJCC 8th edition) NSCLC without EGFR/ALK alterations. Patients received either mono-nivolumab (N) or nivolumab + nab-paclitaxel+ carboplatin (N/C) for three cycles based on PD-L1 expression. The primary endpoint was the major pathological response (MPR). Key secondary endpoints included the pathologic complete response (pCR), objective response rate (ORR), and event-free survival (EFS). Baseline PD-L1 expression and perioperative circulating tumor DNA (ctDNA) status were correlated with pCR and EFS. Fifty-two patients were enrolled, with 46 undergoing surgeries. The MPR was 50.0% (26/52), with 25.0% (13/52) achieving pCR, and 16.7% and 66.7% for patients with PD-L1 >= 50% in N and N/C groups, respectively. Thirteen (25.0%) patients experienced grade 3 or higher immune-related adverse events during neoadjuvant treatment. Patients with post-neoadjuvant ctDNA negativity was more likely to have pCR (39.1%) compared with those remained positive (6.7%, odds ratio = 6.14, 95% CI 0.84-Inf, p = 0.077). With a median follow-up of 25.1 months, the 18-month EFS rate was 64.8% (95% CI 51.9-81.0%). For patients with ctDNA- vs. ctDNA + , the 18m-EFS rate was 93.8% vs 47.3% (HR, 0.15; 95% CI 0.04, 0.94; p = 0.005). Immunochemotherapy may serve as an optimal neoadjuvant treatment even for patients with PD-L1 expression >= 50%. ctDNA negativity following neoadjuvant treatment and surgery could help identify superior pathological and survival benefits, which requires further confirmation in a prospective clinical trial (NCT04015778).
学科与关键词
- Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)Liu, Si-Yang; Chen, Qixun; Zhou, Chengzhi; Zhang, Huizhong; Li, Wen; Chen, Jianhua; Hu, Jian; Wu, Lin; Chen, Qunqing; Dai, Qiangsheng; Shan, Jian-Zhen; Xu, Fei; Liu, Si-Yang Maggie*; Wu, Yi-Long*Cancer Immunology, Immunotherapy, 2023, 72(7): 2257-2265.被引 3
- Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysisZhang, Chao; Chen, Hua-Fei; Yan, Shi; Wu, Lin; Yan, Li-Xu; Yan, Xiao-Long; Yue, Dong-Sheng; Xu, Chun-Wei; Zheng, Min; Li, Ji-Sheng; Liu, Si-Yang; Yang, Ling-Ling; Jiang, Ben-Yuan; Ou, Qiu-Xiang; Qiu, Zhen-Bin; Shao, Yang; Wu, Yi-Long; Zhong, Wen-Zhao*npj Precision Oncology, 2022, 6(1): 66.被引 10
- Neoadjuvant immunotherapy for non-small cell lung cancer: State of the artKang, Jin; Zhang, Chao; Zhong, Wen-Zhao*Cancer Communications, 2021, 41(4): 287-302.被引 62
